Search clinical trials for: PF-06755347 intravenous

Total 7667 results

Pfizer

Terminated

A First in HumanTrial to Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-06755347

Healthy | Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | Primary Immune Thrombocytopenia

Spain, United States, Belgium, United Kingdom, New Zealand
Pfizer

Active, not recruiting

A Preliminary Study to Evaluate PF-07264660 in Healthy Participants

Healthy

United States
Pfizer

Completed

To Calculate the Pharmacokinetics (Concentration of Compound in and Rate of Excretion From the Blood) Following a Very Low Dose of Compound Which Will Not Have Any Pharmacological Activity

Healthy

United Kingdom
Pfizer

Completed

A Drug-Drug Interaction Study Between PF-06882961 and PF-06865571 in Healthy Adult Participants and Overweight Adults or Adults With Obesity Who Are Otherwise Healthy

Healthy Volunteer

United States
Pfizer

Completed

A DRUG-DRUG INTERACTION STUDY BETWEEN PF-06650833 AND PF-06651600 FOLLOWING MULTIPLE DOSES IN HEALTHY PARTICIPANTS

Healthy

United States
Pfizer

Completed

A Study To Examine Safety, Pharmacokinetics, And Pharmacodynamic Of Pf 06412562 In Subjects With Schizophrenia

Schizophrenia

United States
University of Florida

Completed

Potato Fiber and Gastrointestinal Function: Phase 3

Gastrointestinal Symptoms | Stool Frequency | Gastrointestinal Transit Time

United States
Pfizer

Completed

A Study to Understand the Effect of Tablet Formulation and Food on PF-06821497 in Healthy Adult Participants.

Healthy

United States
Pfizer

Completed

A First-in-human Study of Multiple Doses of Topically Administered PF-07295324 and PF-07259955

Healthy

United States
Pfizer

Completed

A Study To Assess The Safety Of PF-06342674 In Healthy Volunteers

Healthy

United States
Pfizer

Completed

Study To Evaluate Safety, Tolerability, And Pharmacokinetics Of PF-06473871 In Normal Healthy Adults

Healthy

Belgium
Pfizer

Completed

A Study To Observe Safety And Blood Concentrations Of PF-06412562 During And Following The Oral Administration Of Multiple Doses Of PF-06412562 In Healthy Adult Volunteers

Healthy

United States
Pfizer

Completed

A Study To Observe Safety And Concentrations Of PF-05297909 And Proteins In Both Blood And Cerebrospinal Fluid After A Single Dose Of PF-05297909 In Healthy Adults

Healthy

United States
Pfizer

Recruiting

A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis

Atopic Dermatitis

United States, Canada
Pfizer

Withdrawn

A Study To Examine The Safety And Efficacy Of PF-00610355 In Moderately Asthmatic Subjects (A7881006)

Respiratory Tract Diseases | Bronchial Diseases | Lung Diseases, Obstructive | Asthma, Bronchial
Pfizer

Not yet recruiting

A Study to Learn How the Medicine Called [14C] PF-06821497 is Taken up Into and Removed From the Body.

Healthy Participants
Pfizer

Completed

A Study To Observe Safety And Blood Concentrations Of PF-04995274 During And Following the Administration of Multiple Doses Of PF-04995274 In Healthy Adult And Healthy Elderly Volunteers.

Healthy

United States
Pfizer

Completed

A Study to Understand How the Study Medicine (PF-07081532) is Processed and Eliminated in Healthy Men

Healthy Participants

Netherlands
Pfizer

Withdrawn

A Study To Look At Safety And Blood Concentrations After Multiple Doses Of PF-03382792 In Healthy Elderly Individuals

Healthy
Pfizer

Terminated

A Study To Examine Safety, Pharmacokinetics, And Pharmacodynamic Of Pf 06412562 In Healthy Males

Healthy

United States
Pfizer

Completed

Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA) (MIRNA)

Nonalcoholic Fatty Liver Disease | Nonalcoholic Steatohepatitis With Liver Fibrosis

Hong Kong, United States, Taiwan, Puerto Rico, China, Canada, Korea, Republic of, Bulgaria, Japan, India, Poland, Slovakia
Pfizer

Completed

A Study To Observe Safety And Blood Concentrations Of PF-06649751 During And Following The Oral Administration Of Multiple Doses Of PF-06649751 In Healthy Adult Western and Japanese Volunteers

Healthy

United States
Pfizer

Completed

A Study in Healthy Adult Male Participants to Assess Absorption, Distribution, Metabolism and Excretion (ADME) of Radiolabeled PF-06865571.

Healthy Participants

United States
Pfizer

Completed

A Study To Assess The Safety Of PF-06342674 In Adults With Type 1 Diabetes

Diabetes Mellitus, Type 1

United States
Pfizer

Recruiting

A Study to Learn About the Study Medicine Called PF-07868489 in Healthy Adult People and in People With Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension

United States
Pfizer

Completed

STUDY OF PF-07321332 IN HEALTHY PARTICIPANTS

Healthy Participants

United States, Belgium
Pfizer

Completed

A Study To Investigate How The Body Handles Multiple Doses Of PF-0243873 And To Investigate The Effect Of PF-02413873 On Sex Hormone Levels In Healthy Young Women

Endometriosis

United States, Belgium
Pfizer

Completed

A Phase 1 Study To Evaluate The Safety And Tolerability Of PF-06252616 In Healthy Subjects

Healthy

United States
Pfizer

Completed

A Study to Understand What the Body Does to the Study Medicine Called PF-07220060 When Taken by Healthy Adults

Healthy Participants

Netherlands
Pfizer

Completed

Study Of PF-06817024 In Healthy Subjects, In Patients With Chronic Rhinosinusitis With Nasal Polyps And in Patients With Atopic Dermatitis

Healthy | Chronic Rhinosinusitis With Nasal Polyps | Atopic Dermatitis

United States
Pfizer

Completed

A Study to Evaluate Safety and Efficacy of PF-06826647 For Moderate To Severe Plaque Psoriasis

Psoriasis

Canada, United States, Japan, Poland
Pfizer

Completed

A Study To Evaluate D1 Receptor Occupancy (RO) Following Single Dose of PF-06412562 In Healthy Male Volunteers (PET)

Healthy

Sweden
Pfizer

Completed

A Study To Evaluate The PDE10 Enzyme Occupancy Following A Single Dose Of PF-02545920 In Healthy Male Volunteers (PET)

Healthy

Sweden
Pfizer

Active, not recruiting

Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.

Renal Cell Carcinoma | Gastric Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Squamous Cell Carcinoma of the Head and Neck | Bile Duct Cancer | Endometrial Cancer | Urothelial Cancer | Lung Squamous Cell Carcinoma | Melanoma Cancer

United States, Taiwan, Korea, Republic of, Australia, Slovakia
Invicro

Completed

D1 Receptor Occupancy (RO) Following a Single Dose of PF-06412562

Healthy Male Volunteers

United States
Pfizer

Completed

A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis.

Plaque Psoriasis | Atopic Dermatitis

United States, Canada, United Kingdom, Japan
Pfizer

Completed

A Study to Understand the Effect of Low-Fat and High-Fat Meals on the Medicine Called PF-07284890 in Healthy Adults

Healthy Participants

United States
Pfizer

Terminated

A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR)

Prostatic Neoplasms

United States
Pfizer

Completed

Study to Characterize Absorption, Distribution, Metabolism and Excretion of 14C PF-06651600 and to Evaluate the Absolute Oral Bioavailability and Fraction Absorbed of PF-06651600. (B7981011)

Healthy Volunteers

Netherlands
Pfizer

Completed

Study to Compare the Effects of Repeated Doses of an Investigational New Drug and a Placebo on Appetite in Advanced Cancer and Anorexia

Anorexia | Breast Cancer | Fatigue | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Prostate Cancer | Cachexia | Non-small Cell Lung Cancer | Loss of Appetite

United States, Canada
Pfizer

Withdrawn

Distribution of a Single IV Dose Of [124I]-Pf 06687234 and Pf 06687234 Assessed With PET-CT Imaging In Moderate To Severe Ulcerative Colitis and Crohn's Disease

Inflammatory Bowel Disease

United States
Pfizer

Completed

A Phase 1 Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-05230907 In Healthy Volunteers

Healthy

Belgium
Pfizer

Completed

Study of Pharmacodynamics and Safety of DGAT2i and ACCi Coadministered in Participants With Sponsor-defined Presumed Non Alcoholic Steatohepatitis

Nonalcoholic Fatty Liver Disease | Nonalcoholic Steatohepatitis

United States, Canada
Pfizer

Completed

Multiple IV Dose Study Of PF-04360365 In Patients With Mild To Moderate Alzheimer's Disease

Alzheimer's Disease

Korea, Republic of, Canada, United States, Australia, United Kingdom, Belgium
Pfizer

Completed

A Study To Determine The Safety, Tolerability, Skin Irritation Potential, And PK Following Topical Application Of PF-07038124 In Healthy Participants

Dermatitis Atopic

United States
Pfizer

Withdrawn

The Bioavailability of a Spray Dried Dispersion Solid Dose Formulation of PF-06260414 Relative to a Suspension Formulation

Healthy

United States
Pfizer

Terminated

A Single Dose Study Of PF-06291874 In Healthy Adult Subjects

Healthy

United States
Pfizer

Terminated

A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)

Multiple Sclerosis

United States
Pfizer

Completed

PF-06651600 for the Treatment of Alopecia Areata (ALLEGRO-2b/3)

Alopecia Areata

China, United States, Spain, Korea, Republic of, Taiwan, Canada, Australia, Germany, Czechia, Poland, Hungary, Japan, United Kingdom, Argentina, Chile, Colombia, Mexico, Russian Federation
Pfizer

Not yet recruiting

A Study to Learn How Different Forms of the Study Medicine Called PF-06954522 Are Taken up Into the Blood in Healthy Adults

Healthy Participants

United States

3

Subscribe